Lyell Immunopharma, Inc. (LYEL) stock
LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.67−0.98 (-6.69%)
Close on Nov 17, 2026Market cap $334.98MP/E –Yield –
Lyell Immunopharma operating margin
Operating margin is operating income as a percentage of revenue.
Lyell Immunopharma's operating margin for the twelve months ending Jun 30, 2026 was -949981.5%. For fiscal 2025 it was -748344.4%, against -588123.0% the year before. The highest annual figure on record is -220.9% in fiscal 2022.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -748344.4% | −160221.5 |
| FY2024 | Dec 31, 2024 | -588123.0% | −398116.8 |
| FY2023 | Dec 31, 2023 | -190006.2% | −189785.3 |
| FY2022 | Dec 31, 2022 | -220.9% | +1795.8 |
| FY2021 | Dec 31, 2021 | -2016.7% | +715.9 |
| FY2020 | Dec 31, 2020 | -2732.6% | +12806.1 |
| FY2019 | Dec 31, 2019 | -15538.7% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1183425.0% | −594175.0 |
| Q1 FY2026 | Mar 31, 2026 | -2213050.0% | −1393521.4 |
| Q4 FY2025 | Dec 31, 2025 | -2127400.0% | −298790.9 |
| Q3 FY2025 | Sep 30, 2025 | -248353.3% | −99809.2 |
| Q2 FY2025 | Jun 30, 2025 | -589250.0% | −192880.8 |
| Q1 FY2025 | Mar 31, 2025 | -819528.6% | +1032971.4 |
| Q4 FY2024 | Dec 31, 2024 | -1828609.1% | −1370855.2 |
| Q3 FY2024 | Sep 30, 2024 | -148544.1% | +87611.9 |
| Q2 FY2024 | Jun 30, 2024 | -396369.2% | −152276.6 |
| Q1 FY2024 | Mar 31, 2024 | -1852500.0% | −1756260.0 |
| Q4 FY2023 | Dec 31, 2023 | -457753.8% | −457723.3 |
| Q3 FY2023 | Sep 30, 2023 | -236156.0% | +1978410.7 |
| Q2 FY2023 | Jun 30, 2023 | -244092.6% | −243988.3 |
| Q1 FY2023 | Mar 31, 2023 | -96240.0% | −83839.3 |
| Q4 FY2022 | Dec 31, 2022 | -30.6% | +1654.0 |
| Q3 FY2022 | Sep 30, 2022 | -2214566.7% | −2212782.2 |
| Q2 FY2022 | Jun 30, 2022 | -104.3% | +2281.9 |
| Q1 FY2022 | Mar 31, 2022 | -12400.7% | −10136.1 |
| Q4 FY2021 | Dec 31, 2021 | -1684.5% | +25.0 |
| Q3 FY2021 | Sep 30, 2021 | -1784.4% | +1658.8 |
| Q2 FY2021 | Jun 30, 2021 | -2386.1% | +903.4 |
| Q1 FY2021 | Mar 31, 2021 | -2264.6% | – |
| Q4 FY2020 | Dec 31, 2020 | -1709.5% | – |
| Q3 FY2020 | Sep 30, 2020 | -3443.3% | – |
| Q2 FY2020 | Jun 30, 2020 | -3289.5% | – |
See a number that looks wrong?